Human ADAM12 DuoSet ELISA, 5 Plate

• Reactivity: Hu
• Applications: ELISA
• Conjugate: Biotin

Human ADAM12 DuoSet ELISA, 5 Plate Summary

• Source: N/A
• Assay Type: Solid Phase Sandwich ELISA
• Inter-Assay: See PDF Datasheet for details
• Intra-Assay: See PDF Datasheet for details
• Spike Recovery: See PDF Datasheet for details
• Sample Volume: See PDF Datasheet for details
• Gene: ADAM12

Applications/Dilutions

• Dilutions:
  • ELISA
• Application Notes: No significant interference observed with available related molecules.

Packaging, Storage & Formulations

• Storage: Store the unopened product at 2 - 8 °C. Do not use past expiration date.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Human ADAM12 DuoSet ELISA, 5 Plate

• a disintegrin and metalloproteinase domain 12 (meltrin alpha)
• ADAM 12
• ADAM metallopeptidase domain 12
• ADAM12
• disintegrin and metalloproteinase domain-containing protein 12
• EC 3.4.24
• EC 3.4.24.58
• MCMP
• MCMPMltna
• Meltrin alpha
• meltrin-alpha
• MLTNA
• MLTNEC 3.4.24.-

Background

Members of the ADAM or MDC (Metalloprotease, Disintegrin, Cysteine-rich) family contain pro, metalloprotease-like, disintegrin-like, cysteine-rich, transmembrane and cytoplasmic domains. They play a fundamental role in diverse processes such as asthma, development, angiogenesis and cancer through their activities in cell adhesion/fusion, membrane protein shedding, and signal transduction. Over 30 members have been identified and about half of them are active metalloproteases such as ADAM8, 9, 10, 12 and 17/TACE.

Publications for ADAM12 (DY4416-05)(4)

Publications using DY4416-05

• S Rutecki, P Szulc, M Paku?a, P Uruski, A Radziemski, E Naumowicz, R Moszy?ski, A Tykarski, J Miku?a-Pie, K Ksi??ek Pro-cancerogenic effects of spontaneous and drug-induced senescence of ovarian cancer cells in vitro and in vivo: a comparative analysis Journal of ovarian research, 2022-07-26;15(1):87. 2022-07-26 [PMID: 35883110] (Human)
• S Ten Hoorn, C Waasdorp, MGH van Oijen, H Damhofer, A Trinh, L Zhao, LJH Smits, S Bootsma, GW van Pelt, WE Mesker, L Mol, KKH Goey, M Koopman, JP Medema, JB Tuynman, I Zlobec, CJA Punt, L Vermeulen, MF Bijlsma Serum-based measurements of stromal activation through ADAM12 associate with poor prognosis in colorectal cancer BMC Cancer, 2022-04-12;22(1):394. 2022-04-12 [PMID: 35413826] (Human)
• EA Ebbing, AP van der Za, A Steins, A Creemers, S Hermsen, R Rentenaar, M Klein, C Waasdorp, GKJ Hooijer, SL Meijer, KK Krishnadat, CJA Punt, MI van Berge, SS Gisbertz, OM van Delden, MCCM Hulshof, JP Medema, HWM van Laarho, MF Bijlsma Stromal-derived interleukin 6 drives epithelial-to-mesenchymal transition and therapy resistance in esophageal adenocarcinoma Proc. Natl. Acad. Sci. U.S.A., 2019-01-22;0(0):. 2019-01-22 [PMID: 30670657] (Human)
• VL Veenstra, H Damhofer, C Waasdorp, LB van Rijsse, MJ van de Vij, F Dijk, HW Wilmink, MG Besselink, OR Busch, DK Chang, PJ Bailey, AV Biankin, HM Kocher, JP Medema, JS Li, R Jiang, DW Pierce, HWM van Laarho, MF Bijlsma ADAM12 is a circulating marker for stromal activation in pancreatic cancer and predicts response to chemotherapy Oncogenesis, 2018-11-16;7(11):87. 2018-11-16 [PMID: 30442938] (Human)

Bioinformatics

• Gene Symbol: ADAM12